CLINICAL TRIALS PROFILE FOR CINACALCET HYDROCHLORIDE
✉ Email this page to a colleague
All Clinical Trials for CINACALCET HYDROCHLORIDE
Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
---|---|---|---|---|---|---|
NCT00094484 ↗ | Cinacalcet HCl in Chronic Kidney Disease Subjects With Secondary Hyperparathyroidism Not Receiving Dialysis | Completed | Amgen | Phase 3 | 2004-10-01 | The purpose of this study is to evaluate the efficacy and safety of cinacalcet compared with placebo in patients with stage 3 and 4 Chronic Kidney Disease (CKD). |
NCT00110890 ↗ | A Research Study for Patients With End-Stage Renal Disease (ESRD) | Completed | Amgen | Phase 4 | 2004-05-01 | The purpose of this study is to evaluate the ability of a treatment strategy, that includes cinacalcet for the management of secondary hyperparathyroidism, to control parathyroid hormone (PTH) compared with the standard of care. |
NCT00113945 ↗ | Research Study Evaluating Cinacalcet for Patients With End Stage Renal Disease (ESRD) | Completed | Amgen | Phase 2 | 2003-07-01 | The purpose of this study is to observe the effects of a treatment strategy that incorporates cinacalcet HCl into the management of secondary hyperparathyroidism (HPT) in subjects with ESRD receiving hemodialysis, on bio-intact parathyroid hormone (biPTH), corrected serum calcium, serum phosphorus, and calcium phosphorus product. |
NCT00113958 ↗ | Cinacalcet Study to Reach Kidney Disease Outcomes Quality Initiative (K/DOQI) Levels | Completed | Amgen | Phase 2 | 1969-12-31 | The purpose of this study is to observe the effects of a treatment strategy that incorporates cinacalcet HCl into the management of secondary hyperparathyroidism (HPT) to K/DOQI recommended targets in subjects with end stage renal disease (ESRD) receiving hemodialysis, on bio-intact parathyroid hormone, corrected serum calcium, serum phosphorus, and calcium phosphorus product. |
NCT00117052 ↗ | SENSOR: Study to Investigate Cinacalcet Treatment in Haemodialysis Patients With Secondary Hyperparathyroidism | Completed | Amgen | Phase 3 | 2004-09-01 | The purpose of this study is to demonstrate that the efficacy of cinacalcet when co-administered with the first meal after dialysis is comparable (non-inferior) to the efficacy of cinacalcet when administered during the dialysis study visit. |
NCT00195936 ↗ | Effect of Cinacalcet on Parathyroid Hormone Secretion in Children and Adolescents With Hypophosphatemic Rickets | Completed | Children's Mercy Hospital Kansas City | Phase 1 | 2005-06-01 | This study will measure the effect of cinacalcet (Sensipar) on parathyroid hormone (PTH) secretion in children and adolescents with hypophosphatemic rickets (XLH). The investigators are seeking evidence that patients with XLH may benefit from treatment with cinacalcet by achieving better control of PTH secretion. |
>Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for CINACALCET HYDROCHLORIDE
Condition Name
Clinical Trial Locations for CINACALCET HYDROCHLORIDE
Trials by Country
Clinical Trial Progress for CINACALCET HYDROCHLORIDE
Clinical Trial Phase
Clinical Trial Sponsors for CINACALCET HYDROCHLORIDE
Sponsor Name